Evolving strategies for the treatment of microvascular angina in women

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 11, 2012, Pages 1413-1419

  Duvernoy, Claire S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

cardiac syndrome X; coronary flow reserve; endothelial dysfunction; microvascular angina; Women's Ischemic Syndrome Evaluation

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ARGININE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ESTRADIOL; ESTRATEST; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; ISOSORBIDE 5 NITRATE; NITRATE; PLACEBO; PRAVASTATIN; PROPRANOLOL; QUINAPRIL; RANOLAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

ANGIOCARDIOGRAPHY; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY SPASM; CORONARY FLOW RESERVE; DRUG EFFICACY; ELECTROCARDIOGRAM; ENDOTHELIAL DYSFUNCTION; ESTROGEN THERAPY; FEMALE; HEADACHE; HUMAN; KINESIOTHERAPY; LIFESTYLE MODIFICATION; MICROCIRCULATION; MIGRAINE; NON INVASIVE MEASUREMENT; PERIPHERAL EDEMA; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; REVIEW; RISK MANAGEMENT; STRESS ECHOCARDIOGRAPHY; SURVIVAL; SYNDROME X; TACHYCARDIA; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; WEIGHT REDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMBINED MODALITY THERAPY; CORONARY CIRCULATION; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; EXERCISE; FEMALE; HUMANS; MICROVASCULAR ANGINA; MICROVESSELS; MUSCLE, SMOOTH, VASCULAR; PROGNOSIS; RISK FACTORS; WOMEN'S HEALTH;

EID: 84871345739     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.55     Document Type: Review

References (40)

1. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J. Am. Coll. Cardiol. 54(17), 1561-1575 (2009).
2. Lanza GA. Cardiac syndrome X: a critical overview and future perspectives. Heart 93(2), 159-166 (2007).
3. Chilian WM, Dellsperger KC, Layne SM et al. Effects of atherosclerosis on the coronary microcirculation. Am. J. Physiol. 258(2 Pt 2), H529-H539 (1990).
4. Treasure CB, Klein JL, Vita JA et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 87(1), 86-93 (1993).
5. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J. Am. Coll. Cardiol. 41(8), 1387-1393 (2003).
6. Campisi R, Czernin J, Schöder H et al. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation 98(2), 119-125 (1998).
7. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286(2), R233-R249 (2004).
8. Gulati M, Cooper-Dehoff RM, McClure C et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch. Intern. Med. 169(9), 843-850 (2009).
9. Robinson JG, Wallace R, Limacher M et al. Elderly women diagnosed with nonspecific chest pain may be at increased cardiovascular risk. J. Womens. Health (Larchmt) 15(10), 1151-1160 (2006).
10. Banks K, Puttagunta D, Murphy S et al. Clinical characteristics, vascular function, and inflammation in women with angina in the absence of coronary atherosclerosis: the Dallas Heart Study. JACC. Cardiovasc. Imaging 4(1), 65-73 (2011).
11. Bugiardini R, Bairey Merz CN. Angina with "normal" coronary arteries: a changing philosophy. JAMA 293(4), 477-484 (2005).
12. Boøttcher M, Botker HE, Sonne H, Nielsen TT, Czernin J. Endotheliumdependent and -independent perfusion reserve and the effect of l-arginine on myocardial perfusion in patients with syndrome X. Circulation 99(14), 1795-1801 (1999).
13. Pepine CJ, Kerensky RA, Lambert CR et al. Some thoughts on the vasculopathy of women with ischemic heart disease. J. Am. Coll. Cardiol. 47(Suppl. 3), S30-S35 (2006).
14. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 108(4), 457-463 (2003).
15. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348(7), 593-600 (2003).
16. Sicari R, Nihoyannopoulos P, Evangelista A et al.; European Association of Echocardiography. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur. J. Echocardiogr. 9(4), 415-437 (2008).
17. Camici PG, Crea F. Coronary microvascular dysfunction. N. Engl. J. Med. 356(8), 830-840 (2007).
18. Reis SE, Holubkov R, Conrad Smith AJ et al.; WISE Investigators. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am. Heart J. 141(5), 735-741 (2001).
19. Pepine CJ, Anderson RD, Sharaf BL et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J. Am. Coll. Cardiol. 55(25), 2825-2832 (2010).
20. von Mering GO, Arant CB, Wessel TR et al.; National Heart, Lung, and Blood Institute. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109(6), 722-725 (2004).
21. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101(9), 948-954 (2000).
22. Schindler TH, Nitzsche EU, Schelbert HR et al. Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiovascular events. J. Am. Coll. Cardiol. 45(9), 1505-1512 (2005).
23. Johnson BD, Shaw LJ, Buchthal SD et al.; National Institutes of Health-National Heart, Lung, and Blood Institute. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109(24), 2993-2999 (2004).
24. Panting JR, Gatehouse PD, Yang GZ et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N. Engl. J. Med. 346(25), 1948-1953 (2002).
25. Bugiardini R, Borghi A, Biagetti L, Puddu P. Comparison of verapamil versus propranolol therapy in syndrome X. Am. J. Cardiol. 63(5), 286-290 (1989).
26. Lanza GA, Colonna G, Pasceri V, Maseri A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am. J. Cardiol. 84(7), 854-856, A8 (1999).
27. Masumoto A, Mohri M, Takeshita A. Three-year follow-up of the Japanese patients with microvascular angina attributable to coronary microvascular spasm. Int. J. Cardiol. 81(2-3), 151-156 (2001).
28. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin- converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am. J. Cardiol. 90(9), 974-982 (2002).
29. Pauly DF, Johnson BD, Anderson RD et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin- converting enzyme inhibition is associated with improved microvascular function: a double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). Am. Heart J. 162(4), 678-684 (2011).
30. Mehta PK, Goykhman P, Thomson LE et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC. Cardiovasc. Imaging 4(5), 514-522 (2011).
31. Cannon RO 3rd, Quyyumi AA, Mincemoyer R et al. Imipramine in patients with chest pain despite normal coronary angiograms. N. Engl. J. Med. 330(20), 1411-1417 (1994).
32. Lerman A, Burnett JC Jr, Higano ST, McKinley LJ, Holmes DR Jr. Long-term l-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 97(21), 2123-2128 (1998).
33. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by l-arginine. Lancet 338(8782-8783), 1546-1550 (1991).
34. Treasure CB, Klein JL, Weintraub WS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332(8), 481-487 (1995).
35. Kayikcioglu M, Payzin S, Yavuzgil O, Kultursay H, Can LH, Soydan I. Benefits of statin treatment in cardiac syndrome-X1. Eur. Heart J. 24(22), 1999-2005 (2003).
36. Rosano GM, Collins P, Kaski JC, Lindsay DC, Sarrel PM, Poole-Wilson PA. Syndrome X in women is associated with oestrogen deficiency. Eur. Heart J. 16(5), 610-614 (1995).
37. Rosano GM, Peters NS, Lefroy D et al. 17-beta-estradiol therapy lessens angina in postmenopausal women with syndrome X. J. Am. Coll. Cardiol. 28(6), 1500-1505 (1996).
38. Adamson DL, Webb CM, Collins P. Esterified estrogens combined with methyltestosterone improve emotional well-being in postmenopausal women with chest pain and normal coronary angiograms. Menopause 8(4), 233-238 (2001).
39. Eriksson BE, Tyni-Lennè R, Svedenhag J et al. Physical training in syndrome X: physical training counteracts deconditioning and pain in syndrome X. J. Am. Coll. Cardiol. 36(5), 1619-1625 (2000).
40. Shaw LJ, Olson MB, Kip K et al. The value of estimated functional capacity in estimating outcome: results from the NHBLI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. J. Am. Coll. Cardiol. 47(Suppl. 3), S36-S43 (2006).